Interview with Deepak Khanna, Senior Vice President and Managing Director UK,…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Address: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, United Kingdom
Tel: +44 (0) 1992 467272
Merck Sharp & Dohme Limited (MSD) is the UK subsidiary of Merck & Co., Inc., of Whitehouse Station, New Jersey, USA, a leading research-based pharmaceutical company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products to improve human health.
MSD has committed substantial investment to research and manufacturing in the UK because of the unrivalled scientific excellence and skills base available here. It has two sites in the UK: headquarters and pharmaceutical research and development laboratories in Hoddesdon, Hertfordshire; and manufacturing at Cramlington in Northumberland.
x MSD employs approximately 1,400 people in the UK
x MSD’s UK headquarters are located in Hoddesdon, Hertfordshire, where the company’s sales and marketing, medical services, market research and administration functions are situated
x Pharmaceutical research and development is also located at Hoddesdon. Recent investment has established Hoddesdon as a global centre of expertise in chemistry, to serve Merck & Co., Inc.’s organic and synthetic chemistry needs
x The pharmaceutical manufacturing and supply centre in Cramlington, Northumberland, continues to lead the industry and the Merck & Co., Inc. organisation in productivity, delivering important medicines to the Merck network
x There are additional administrative offices in both London and Stockley Park
x MSD has played a key role in the development of five of Merck & Co., Inc.’s products 16 medicines are manufactured in the UK by MSD
x The UK turnover in 2007 was £382 million
x The UK Sales Force is made up of around 500 field-based employees
MSD’s mission is to provide superior medicines which enhance patients’ quality of life. Of Merck & Co., Inc.’s most popular medicines, five have been discovered and 16 are manufactured by MSD in the UK.
MSD’s product portfolio covers a range of key therapy areas including atherosclerosis and cardiovascular disease, diabetes, infectious diseases, neuroscience and ophthalmology, respiratory, bone, arthritic conditions, and vaccines.
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from overseas. Additionally, UK firms are looking to poach EMA staff as it heads to Amsterdam…
Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal…
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your…
See our Cookie Privacy Policy Here